<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38543815</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Small Molecules for the Treatment of Long-COVID-Related Vascular Damage and Abnormal Blood Clotting: A Patent-Based Appraisal.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">450</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16030450</ELocationID><Abstract><AbstractText>People affected by COVID-19 are exposed to, among others, abnormal clotting and endothelial dysfunction, which may result in deep vein thrombosis, cerebrovascular disorders, and ischemic and non-ischemic heart diseases, to mention a few. Treatments for COVID-19 include antiplatelet (e.g., aspirin, clopidogrel) and anticoagulant agents, but their impact on morbidity and mortality has not been proven. In addition, due to viremia-associated interconnected prothrombotic and proinflammatory events, anti-inflammatory drugs have also been investigated for their ability to mitigate against immune dysregulation due to the cytokine storm. By retrieving patent literature published in the last two years, small molecules patented for long-COVID-related blood clotting and hematological complications are herein examined, along with supporting evidence from preclinical and clinical studies. An overview of the main features and therapeutic potentials of small molecules is provided for the thromboxane receptor antagonist ramatroban, the pan-caspase inhibitor emricasan, and the sodium-hydrogen antiporter 1 (NHE-1) inhibitor rimeporide, as well as natural polyphenolic compounds.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Samarelli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6753-3528</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graziano</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5575-3240</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gambacorta</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1965-1519</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graps</LastName><ForeName>Elisabetta Anna</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>ARESS Puglia-Agenzia Regionale Strategica per la Salute ed il Sociale, I-70121 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonetti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-2043-7464</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolotti</LastName><ForeName>Orazio</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6533-5539</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, I-70125 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altomare</LastName><ForeName>Cosimo Damiano</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0001-5016-5805</Identifier><AffiliationInfo><Affiliation>ARESS Puglia-Agenzia Regionale Strategica per la Salute ed il Sociale, I-70121 Bari, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">caspase inhibitors</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">procyanidins</Keyword><Keyword MajorTopicYN="N">ramatroban</Keyword><Keyword MajorTopicYN="N">vascular issues</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38543815</ArticleId><ArticleId IdType="pmc">PMC10976273</ArticleId><ArticleId IdType="doi">10.3390/v16030450</ArticleId><ArticleId IdType="pii">v16030450</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., Haagmans B.L., Lauber C., Leontovich A.M., Neuman B.W., et al. The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and Naming It SARS-CoV-2. Nat. Microbiol. 2020;5:536&#x2013;544. doi: 10.1038/s41564-020-0695-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0695-z</ArticleId><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The Cytokine Storm and COVID-19. J. Med. Virol. 2021;93:250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagoor Meeran M.F., Sharma C., Goyal S.N., Kumar S., Ojha S. CB2 Receptor-Selective Agonists as Candidates for Targeting Infection, Inflammation, and Immunity in SARS-CoV-2 Infections. Drug Dev. Res. 2021;82:7&#x2013;11. doi: 10.1002/ddr.21752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21752</ArticleId><ArticleId IdType="pmc">PMC7753678</ArticleId><ArticleId IdType="pubmed">33190277</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Qin C., Fei Y., Shen M., Zhou Y., Zhang Y., Zeng X., Zhang S. Anti-Inflammatory and Immune Therapy in Severe Coronavirus Disease 2019 (COVID-19) Patients: An Update. Clin. Immunol. 2022;239:109022. doi: 10.1016/j.clim.2022.109022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109022</ArticleId><ArticleId IdType="pmc">PMC9040414</ArticleId><ArticleId IdType="pubmed">35477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Graziano G., Delre P., Carofiglio F., Brea J., Ligresti A., Kostrzewa M., Riganti C., Gio&#xe8;-Gallo C., Majellaro M., Nicolotti O., et al. N-Adamantyl-Anthranil Amide Derivatives: New Selective Ligands for the Cannabinoid Receptor Subtype 2 (CB2R) Eur. J. Med. Chem. 2023;248:115109. doi: 10.1016/j.ejmech.2023.115109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115109</ArticleId><ArticleId IdType="pubmed">36657299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasperi V., Guzzo T., Topai A., Gambacorta N., Ciriaco F., Nicolotti O., Maccarrone M. Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and Their Therapeutic Potential. Curr. Med. Chem. 2023;30:1420&#x2013;1457. doi: 10.2174/0929867329666220825161603.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867329666220825161603</ArticleId><ArticleId IdType="pubmed">36028971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambacorta N., Ciriaco F., Amoroso N., Altomare C.D., Bajorath J., Nicolotti O. CIRCE: Web-Based Platform for the Prediction of Cannabinoid Receptor Ligands Using Explainable Machine Learning. J. Chem. Inf. Model. 2023;63:5916&#x2013;5926. doi: 10.1021/acs.jcim.3c00914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.3c00914</ArticleId><ArticleId IdType="pubmed">37675493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambacorta N., Gasperi V., Guzzo T., Di Leva F.S., Ciriaco F., S&#xe1;nchez C., Tullio V., Rozzi D., Marinelli L., Topai A., et al. Exploring the 1,3-Benzoxazine Chemotype for Cannabinoid Receptor 2 as a Promising Anti-Cancer Therapeutic. Eur. J. Med. Chem. 2023;259:115647. doi: 10.1016/j.ejmech.2023.115647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115647</ArticleId><ArticleId IdType="pubmed">37478557</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Reed A., Desai S.R., Devaraj A., Faiez T.S., Laverty S., Kanwal A., Esneau C., Liu M.K.C., Kamal F., et al. A Persistent Neutrophil-Associated Immune Signature Characterizes Post&#x2013;COVID-19 Pulmonary Sequelae. Sci. Transl. Med. 2022;14:eabo5795. doi: 10.1126/scitranslmed.abo5795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5795</ArticleId><ArticleId IdType="pubmed">36383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Cuadrado M.L., Florencio L.L. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. Int. J. Environ. Res. Public Health. 2021;18:2621. doi: 10.3390/ijerph18052621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18052621</ArticleId><ArticleId IdType="pmc">PMC7967389</ArticleId><ArticleId IdType="pubmed">33807869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambacorta N., Caputo L., Quintieri L., Monaci L., Ciriaco F., Nicolotti O. Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease. Biomedicines. 2022;10:1067. doi: 10.3390/biomedicines10051067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10051067</ArticleId><ArticleId IdType="pmc">PMC9139167</ArticleId><ArticleId IdType="pubmed">35625804</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanelli I., Corona A., Cerchia C., Cassese E., Improta S., Costanzi E., Pelliccia S., Morasso S., Esposito F., Paulis A., et al. Broad-Spectrum Coronavirus 3C-like Protease Peptidomimetic Inhibitors Effectively Block SARS-CoV-2 Replication in Cells: Design, Synthesis, Biological Evaluation, and X-Ray Structure Determination. Eur. J. Med. Chem. 2023;253:115311. doi: 10.1016/j.ejmech.2023.115311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115311</ArticleId><ArticleId IdType="pmc">PMC10068823</ArticleId><ArticleId IdType="pubmed">37043904</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J.R., Dhodapkar R.M., Lu P., Gehlhausen J.R., Tabachnikova A., Greene K., Tabacof L., Malik A.A., et al. Distinguishing Features of Long COVID Identified through Immune Profiling. Nature. 2023;623:139&#x2013;148. doi: 10.1038/s41586-023-06651-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID Endotheliopathy: Hypothesized Mechanisms and Potential Therapeutic Approaches. J. Clin. Investig. 2022;132:e161167. doi: 10.1172/JCI161167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An Overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-Acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva G., Nasillo V., Tagliafico E., Trenti T., Comoli P., Luppi M. COVID-19: More than a Cytokine Storm. Crit. Care. 2020;24:549. doi: 10.1186/s13054-020-03267-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03267-w</ArticleId><ArticleId IdType="pmc">PMC7472946</ArticleId><ArticleId IdType="pubmed">32887652</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J.H., Levi M., Thachil J. Coagulopathy in COVID-19. J. Thromb. Haemost. 2020;18:2103&#x2013;2109. doi: 10.1111/jth.14975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14975</ArticleId><ArticleId IdType="pmc">PMC7323352</ArticleId><ArticleId IdType="pubmed">32558075</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Wada H., Levy J.H. Platelet Activation and Thrombosis in COVID-19. Semin. Thromb. Hemost. 2023;49:55&#x2013;61. doi: 10.1055/s-0042-1749441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0042-1749441</ArticleId><ArticleId IdType="pubmed">35738296</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncati L., Ligabue G., Nasillo V., Lusenti B., Gennari W., Fabbiani L., Malagoli C., Gallo G., Giovanella S., Lupi M., et al. A Proof of Evidence Supporting Abnormal Immunothrombosis in Severe COVID-19: Naked Megakaryocyte Nuclei Increase in the Bone Marrow and Lungs of Critically Ill Patients. Platelets. 2020;31:1085&#x2013;1089. doi: 10.1080/09537104.2020.1810224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2020.1810224</ArticleId><ArticleId IdType="pubmed">32857624</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhadad S., Redmond D., Tan A., Huang J., Rodriguez B.L., Racine-Brzostek S.E., Subrahmanian S., Ahamed J., Laurence J. Defibrotide Mitigates Endothelial Cell Injury Induced by Plasmas from Patients with COVID-19 and Related Vasculopathies. Thromb. Res. 2023;225:47&#x2013;56. doi: 10.1016/j.thromres.2023.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2023.03.009</ArticleId><ArticleId IdType="pmc">PMC10033153</ArticleId><ArticleId IdType="pubmed">37001283</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.C., Devason A.S., Umana I.C., Cox T.O., Dohnalov&#xe1; L., Litichevskiy L., Perla J., Lundgren P., Etwebi Z., Izzo L.T., et al. Serotonin Reduction in Post-Acute Sequelae of Viral Infection. Cell. 2023;186:4851&#x2013;4867.e20. doi: 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Libby P., Ridker P.M. COVID-19&#x2014;A Vascular Disease. Trends Cardiovasc. Med. 2021;31:1&#x2013;5. doi: 10.1016/j.tcm.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Espacenet.  [(accessed on 1 December 2023)].  Available online:  https://worldwide.espacenet.com/</Citation></Reference><Reference><Citation>Clinical Trials.  [(accessed on 1 December 2023)]; Available online:  https://clinicaltrials.gov/</Citation></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-Term Cardiovascular Outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra M.R., Desai S.S., Kuy S., Henry T.D., Patel A.N. Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. N. Engl. J. Med. 2020;382:e102. doi: 10.1056/NEJMoa2007621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007621</ArticleId><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C., Br&#xfc;ningk S.C., Hoch T., Fan B., Muzio G., Thompson R.C., Ceglarek L., Meledin R., Westermann P., Emmenegger M., et al. Persistent Complement Dysregulation with Signs of Thromboinflammation in Active Long Covid. Science. 2024;383:eadg7942. doi: 10.1126/science.adg7942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncati L., Ligabue G., Fabbiani L., Malagoli C., Gallo G., Lusenti B., Nasillo V., Manenti A., Maiorana A. Type 3 Hypersensitivity in COVID-19 Vasculitis. Clin. Immunol. 2020;217:108487. doi: 10.1016/j.clim.2020.108487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108487</ArticleId><ArticleId IdType="pmc">PMC7256503</ArticleId><ArticleId IdType="pubmed">32479986</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker R.C. COVID-19-Associated Vasculitis and Vasculopathy. J. Thromb. Thrombolysis. 2020;50:499&#x2013;511. doi: 10.1007/s11239-020-02230-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02230-4</ArticleId><ArticleId IdType="pmc">PMC7373848</ArticleId><ArticleId IdType="pubmed">32700024</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark K., Massberg S. Interplay between Inflammation and Thrombosis in Cardiovascular Pathology. Nat. Rev. Cardiol. 2021;18:666&#x2013;682. doi: 10.1038/s41569-021-00552-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00552-1</ArticleId><ArticleId IdType="pmc">PMC8100938</ArticleId><ArticleId IdType="pubmed">33958774</ArticleId></ArticleIdList></Reference><Reference><Citation>Theofilis P., Sagris M., Oikonomou E., Antonopoulos A.S., Siasos G., Tsioufis C., Tousoulis D. Inflammatory Mechanisms Contributing to Endothelial Dysfunction. Biomedicines. 2021;9:781. doi: 10.3390/biomedicines9070781.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9070781</ArticleId><ArticleId IdType="pmc">PMC8301477</ArticleId><ArticleId IdType="pubmed">34356845</ArticleId></ArticleIdList></Reference><Reference><Citation>Purgatorio R., Gambacorta N., de Candia M., Catto M., Rullo M., Pisani L., Nicolotti O., Altomare C.D. First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease. Molecules. 2021;26:5208. doi: 10.3390/molecules26175208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26175208</ArticleId><ArticleId IdType="pmc">PMC8434007</ArticleId><ArticleId IdType="pubmed">34500640</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC, ACTIV-4a, and REMAP-CAP Investigators Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N. Engl. J. Med. 2021;385:790&#x2013;802. doi: 10.1056/NEJMoa2105911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Hempel T., Elez K., Kr&#xfc;ger N., Raich L., Shrimp J.H., Danov O., Jonigk D., Braun A., Shen M., Hall M.D., et al. Synergistic Inhibition of SARS-CoV-2 Cell Entry by Otamixaban and Covalent Protease Inhibitors: Pre-Clinical Assessment of Pharmacological and Molecular Properties. Chem. Sci. 2021;12:12600&#x2013;12609. doi: 10.1039/D1SC01494C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1SC01494C</ArticleId><ArticleId IdType="pmc">PMC8494051</ArticleId><ArticleId IdType="pubmed">34703545</ArticleId></ArticleIdList></Reference><Reference><Citation>De Maio F., Rullo M., de Candia M., Purgatorio R., Lopopolo G., Santarelli G., Palmieri V., Papi M., Elia G., De Candia E., et al. Evaluation of Novel Guanidino-Containing Isonipecotamide Inhibitors of Blood Coagulation Factors against SARS-CoV-2 Virus Infection. Viruses. 2022;14:1730. doi: 10.3390/v14081730.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14081730</ArticleId><ArticleId IdType="pmc">PMC9415951</ArticleId><ArticleId IdType="pubmed">36016352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280.e8. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G., Massari M., Da Cas R., Menniti Ippolito F., Sultana J., Crisafulli S., Giorgi Rossi P., Marino M., Zorzi M., Bovo E., et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Saf. 2020;43:1297&#x2013;1308. doi: 10.1007/s40264-020-00994-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-00994-5</ArticleId><ArticleId IdType="pmc">PMC7450482</ArticleId><ArticleId IdType="pubmed">32852721</ArticleId></ArticleIdList></Reference><Reference><Citation>Huggins D.J. Structural Analysis of Experimental Drugs Binding to the SARS-CoV-2 Target TMPRSS2. J. Mol. Graph. Model. 2020;100:107710. doi: 10.1016/j.jmgm.2020.107710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2020.107710</ArticleId><ArticleId IdType="pmc">PMC7417922</ArticleId><ArticleId IdType="pubmed">32829149</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison S.A., Goodman Z., Jabbar A., Vemulapalli R., Younes Z.H., Freilich B., Sheikh M.Y., Schattenberg J.M., Kayali Z., Zivony A., et al. A Randomized, Placebo-Controlled Trial of Emricasan in Patients with NASH and F1-F3 Fibrosis. J. Hepatol. 2020;72:816&#x2013;827. doi: 10.1016/j.jhep.2019.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2019.11.024</ArticleId><ArticleId IdType="pubmed">31887369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser B.J., Beldar S., Seitova A., Hutchinson A., Mannar D., Li Y., Kwon D., Tan R., Wilson R.P., Leopold K., et al. Structure and Activity of Human TMPRSS2 Protease Implicated in SARS-CoV-2 Activation. Nat. Chem. Biol. 2022;18:963&#x2013;971. doi: 10.1038/s41589-022-01059-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-022-01059-7</ArticleId><ArticleId IdType="pubmed">35676539</ArticleId></ArticleIdList></Reference><Reference><Citation>Guertin K.R., Gardner C.J., Klein S.I., Zulli A.L., Czekaj M., Gong Y., Spada A.P., Cheney D.L., Maignan S., Guilloteau J.-P., et al. Optimization of the &#x3b2;-Aminoester Class of Factor Xa Inhibitors. Part 2: Identification of FXV673 as a Potent and Selective Inhibitor with Excellent In Vivo Anticoagulant Activity. Bioorganic Med. Chem. Lett. 2002;12:1671&#x2013;1674. doi: 10.1016/S0960-894X(02)00213-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-894X(02)00213-5</ArticleId><ArticleId IdType="pubmed">12039587</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiffer A.L., Garlick J.M., Wu Y., Wotring J.W., Arora S., Harmata A.S., Bochar D.A., Stephenson C.J., Soellner M.B., Sexton J.Z., et al. TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform. ACS Med. Chem. Lett. 2023;14:860&#x2013;866. doi: 10.1021/acsmedchemlett.3c00035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.3c00035</ArticleId><ArticleId IdType="pmc">PMC10237299</ArticleId><ArticleId IdType="pubmed">37284689</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang K.C., Rizk J.G., Nelson D.J., Krishnamurti L., Subbian S., Imig J.D., Khan I., Reddy S.T., Gupta A. Ramatroban for Chemoprophylaxis and Treatment of COVID-19: David Takes on Goliath. Expert Opin. Ther. Targets. 2022;26:13&#x2013;28. doi: 10.1080/14728222.2022.2031975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2022.2031975</ArticleId><ArticleId IdType="pmc">PMC10119876</ArticleId><ArticleId IdType="pubmed">35068281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Kalantar-Zadeh K., Reddy S.T. Ramatroban as a Novel Immunotherapy for COVID-19. J. Mol. Genet. Med. 2020;14 doi: 10.37421/jmgm.2020.14.457.</Citation><ArticleIdList><ArticleId IdType="doi">10.37421/jmgm.2020.14.457</ArticleId><ArticleId IdType="pmc">PMC7500620</ArticleId><ArticleId IdType="pubmed">32952595</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroli N., Bhasuran B., Natarajan J., Kolandaivel P. The Potential Role of Procyanidin as a Therapeutic Agent against SARS-CoV-2: A Text Mining, Molecular Docking and Molecular Dynamics Simulation Approach. J. Biomol. Struct. Dyn. 2022;40:1230&#x2013;1245. doi: 10.1080/07391102.2020.1823887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1823887</ArticleId><ArticleId IdType="pmc">PMC7544928</ArticleId><ArticleId IdType="pubmed">32960159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardel&#x10d;&#xed;kov&#xe1; A., Miro&#x161;&#x161;ay A., &#x160;olt&#xfd;s J., Moj&#x17e;i&#x161; J. Therapeutic and Prophylactic Effect of Flavonoids in Post-COVID-19 Therapy. Phytother. Res. 2022;36:2042&#x2013;2060. doi: 10.1002/ptr.7436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.7436</ArticleId><ArticleId IdType="pmc">PMC9111001</ArticleId><ArticleId IdType="pubmed">35302260</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad K.P. Might Proton Pump or Sodium-Hydrogen Exchanger Inhibitors Be of Value to Ameliorate SARS-CoV-2 Pathophysiology? Physiol. Rep. 2021;8:e14649. doi: 10.14814/phy2.14649.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14649</ArticleId><ArticleId IdType="pmc">PMC7762781</ArticleId><ArticleId IdType="pubmed">33369281</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassmeyer M., Alpan O., Corley M.J., Premeaux T.A., Lillard K., Coatney P., Vaziri T., Michalsky S., Pang A.P.S., Bukhari Z., et al. Caspases and Therapeutic Potential of Caspase Inhibitors in Moderate&#x2013;Severe SARS-CoV-2 Infection and Long COVID. Allergy. 2022;77:118&#x2013;129. doi: 10.1111/all.14907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14907</ArticleId><ArticleId IdType="pmc">PMC8222863</ArticleId><ArticleId IdType="pubmed">33993490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogletree M.L., Chander Chiang K., Kulshrestha R., Agarwal A., Agarwal A., Gupta A. Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. Front. Pharmacol. 2022;13:904020. doi: 10.3389/fphar.2022.904020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.904020</ArticleId><ArticleId IdType="pmc">PMC9355466</ArticleId><ArticleId IdType="pubmed">35935851</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Archambault A., Zaid Y., Rakotoarivelo V., Turcotte C., Dor&#xe9; &#xc9;., Dubuc I., Martin C., Flamand O., Amar Y., Cheikh A., et al. High Levels of Eicosanoids and Docosanoids in the Lungs of Intubated COVID-19 Patients. FASEB J. 2021;35:e21666. doi: 10.1096/fj.202100540R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202100540R</ArticleId><ArticleId IdType="pmc">PMC8206770</ArticleId><ArticleId IdType="pubmed">34033145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka T., Matsui T., Okamoto Y., Ohta A., Shichijo M. Ramatroban (BAY u 3405): A Novel Dual Antagonist of TXA2 Receptor and CRTh2, a Newly Identified Prostaglandin D2 Receptor. Cardiovasc. Drug Rev. 2004;22:71&#x2013;90. doi: 10.1111/j.1527-3466.2004.tb00132.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3466.2004.tb00132.x</ArticleId><ArticleId IdType="pubmed">15179446</ArticleId></ArticleIdList></Reference><Reference><Citation>Trisciuzzi D., Siragusa L., Baroni M., Cruciani G., Nicolotti O. An Integrated Machine Learning Model To Spot Peptide Binding Pockets in 3D Protein Screening. J. Chem. Inf. Model. 2022;62:6812&#x2013;6824. doi: 10.1021/acs.jcim.2c00583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.2c00583</ArticleId><ArticleId IdType="pubmed">36320100</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizk J.G., Kalantar-Zadeh K., Mehra M.R., Lavie C.J., Rizk Y., Forthal D.N. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80:1267&#x2013;1292. doi: 10.1007/s40265-020-01367-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01367-z</ArticleId><ArticleId IdType="pmc">PMC7372203</ArticleId><ArticleId IdType="pubmed">32696108</ArticleId></ArticleIdList></Reference><Reference><Citation>Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 Protease Nomenclature. Cell. 1996;87:171. doi: 10.1016/S0092-8674(00)81334-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81334-3</ArticleId><ArticleId IdType="pubmed">8861900</ArticleId></ArticleIdList></Reference><Reference><Citation>Man S.M., Kanneganti T.-D. Converging Roles of Caspases in Inflammasome Activation, Cell Death and Innate Immunity. Nat. Rev. Immunol. 2016;16:7&#x2013;21. doi: 10.1038/nri.2015.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2015.7</ArticleId><ArticleId IdType="pmc">PMC4915362</ArticleId><ArticleId IdType="pubmed">26655628</ArticleId></ArticleIdList></Reference><Reference><Citation>Imre G. Cell Death Signalling in Virus Infection. Cell. Signal. 2020;76:109772. doi: 10.1016/j.cellsig.2020.109772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2020.109772</ArticleId><ArticleId IdType="pmc">PMC7486881</ArticleId><ArticleId IdType="pubmed">32931899</ArticleId></ArticleIdList></Reference><Reference><Citation>Yapasert R., Khaw-on P., Banjerdpongchai R. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets. Molecules. 2021;26:7459. doi: 10.3390/molecules26247459.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26247459</ArticleId><ArticleId IdType="pmc">PMC8706825</ArticleId><ArticleId IdType="pubmed">34946543</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X., Han M., Li T., Sun W., Wang D., Fu B., Zhou Y., Zheng X., Yang Y., Li X., et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. Proc. Natl. Acad. Sci. USA. 2020;117:10970. doi: 10.1073/pnas.2005615117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005615117</ArticleId><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner C.D., Gottlieb R.L., Criner G.J., Arribas L&#xf3;pez J.R., Cattelan A.M., Soriano Viladomiu A., Ogbuagu O., Malhotra P., Mullane K.M., Castagna A., et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020;324:1048&#x2013;1057. doi: 10.1001/jama.2020.16349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Alijotas-Reig J., Esteve-Valverde E., Belizna C., Selva-O&#x2019;Callaghan A., Pardos-Gea J., Quintana A., Mekinian A., Anunciacion-Llunell A., Mir&#xf3;-Mur F. Immunomodulatory Therapy for the Management of Severe COVID-19. Beyond the Anti-Viral Therapy: A Comprehensive Review. Autoimmun. Rev. 2020;19:102569. doi: 10.1016/j.autrev.2020.102569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102569</ArticleId><ArticleId IdType="pmc">PMC7252146</ArticleId><ArticleId IdType="pubmed">32376394</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobler C., Maphumulo S.C., Grobbelaar L.M., Bredenkamp J.C., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B., Pretorius E. COVID-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. Int. J. Mol. Sci. 2020;21:5168. doi: 10.3390/ijms21145168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21145168</ArticleId><ArticleId IdType="pmc">PMC7403995</ArticleId><ArticleId IdType="pubmed">32708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A.J., Rustagi A., Zhao N.Q., Roque J., Mart&#xed;nez-Col&#xf3;n G.J., McKechnie J.L., Ivison G.T., Ranganath T., Vergara R., Hollis T., et al. A Single-Cell Atlas of the Peripheral Immune Response in Patients with Severe COVID-19. Nat. Med. 2020;26:1070&#x2013;1076. doi: 10.1038/s41591-020-0944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Linton S.D., Aja T., Armstrong R.A., Bai X., Chen L.-S., Chen N., Ching B., Contreras P., Diaz J.-L., Fisher C.D., et al. First-in-Class Pan Caspase Inhibitor Developed for the Treatment of Liver Disease. J. Med. Chem. 2005;48:6779&#x2013;6782. doi: 10.1021/jm050307e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm050307e</ArticleId><ArticleId IdType="pubmed">16250635</ArticleId></ArticleIdList></Reference><Reference><Citation>Stack J.H., Beaumont K., Larsen P.D., Straley K.S., Henkel G.W., Randle J.C.R., Hoffman H.M. IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients. J. Immunol. 2005;175:2630&#x2013;2634. doi: 10.4049/jimmunol.175.4.2630.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.4.2630</ArticleId><ArticleId IdType="pubmed">16081838</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z.-Y.D., Liang K., Shetty A.K. Complications of COVID-19 on the Central Nervous System: Mechanisms and Potential Treatment for Easing Long COVID. Aging Dis. 2023;14:1492&#x2013;1510. doi: 10.14336/AD.2023.0312.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2023.0312</ArticleId><ArticleId IdType="pmc">PMC10529748</ArticleId><ArticleId IdType="pubmed">37163427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Zhang J., Cha Y., Kolitz S., Funt J., Escalante Chong R., Barrett S., Kusko R., Zeskind B., Kaufman H. Advanced Bioinformatics Rapidly Identifies Existing Therapeutics for Patients with Coronavirus Disease-2019 (COVID-19) J. Transl. Med. 2020;18:257. doi: 10.1186/s12967-020-02430-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02430-9</ArticleId><ArticleId IdType="pmc">PMC7315012</ArticleId><ArticleId IdType="pubmed">32586380</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpan O., Gupta R., Latterich M., Hubka M., Bukhari Z., Ndhlovu L. D020 role of cellular caspases and therapeutic potential of a pan-caspase inhibitor, emricasan, in COVID-19. Ann. Allergy Asthma Immunol. 2021;127:S15&#x2013;S16. doi: 10.1016/j.anai.2021.08.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2021.08.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Tsao G., Bosch J., Kayali Z., Harrison S.A., Abdelmalek M.F., Lawitz E., Satapathy S.K., Ghabril M., Shiffman M.L., Younes Z.H., et al. Randomized Placebo-Controlled Trial of Emricasan for Non-Alcoholic Steatohepatitis-Related Cirrhosis with Severe Portal Hypertension. J. Hepatol. 2020;72:885&#x2013;895. doi: 10.1016/j.jhep.2019.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2019.12.010</ArticleId><ArticleId IdType="pubmed">31870950</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiffman M., Freilich B., Vuppalanchi R., Watt K., Chan J.L., Spada A., Hagerty D.T., Schiff E. Randomised Clinical Trial: Emricasan versus Placebo Significantly Decreases ALT and Caspase 3/7 Activation in Subjects with Non-Alcoholic Fatty Liver Disease. Aliment. Pharmacol. Ther. 2019;49:64&#x2013;73. doi: 10.1111/apt.15030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15030</ArticleId><ArticleId IdType="pmc">PMC6587784</ArticleId><ArticleId IdType="pubmed">30430605</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial Cell Infection and Endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Ilyas I., Weng J. Endothelial Dysfunction in COVID-19: An Overview of Evidence, Biomarkers, Mechanisms and Potential Therapies. Acta Pharmacol. Sin. 2023;44:695&#x2013;709. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Zhao T., Zhou X., Xiang Y., Gutierrez-Castrellon P., Ma X. Inflammatory Pathways in COVID-19: Mechanism and Therapeutic Interventions. MedComm. 2022;3:e154. doi: 10.1002/mco2.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.154</ArticleId><ArticleId IdType="pmc">PMC9340488</ArticleId><ArticleId IdType="pubmed">35923762</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhlenhut K., H&#xf6;gger P. Facilitated Cellular Uptake and Suppression of Inducible Nitric Oxide Synthase by a Metabolite of Maritime Pine Bark Extract (Pycnogenol) Free Radic. Biol. Med. 2012;53:305&#x2013;313. doi: 10.1016/j.freeradbiomed.2012.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.04.013</ArticleId><ArticleId IdType="pubmed">22569413</ArticleId></ArticleIdList></Reference><Reference><Citation>Zibadi S., Rohdewald P.J., Park D., Watson R.R. Reduction of Cardiovascular Risk Factors in Subjects with Type 2 Diabetes by Pycnogenol Supplementation. Nutr. Res. 2008;28:315&#x2013;320. doi: 10.1016/j.nutres.2008.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nutres.2008.03.003</ArticleId><ArticleId IdType="pubmed">19083426</ArticleId></ArticleIdList></Reference><Reference><Citation>Weichmann F., Rohdewald P. Projected Supportive Effects of Pycnogenol&#x24c7; in Patients Suffering from Multi-Dimensional Health Impairments after a SARS-CoV2 Infection. Int. J. Antimicrob. Agents. 2020;56:106191. doi: 10.1016/j.ijantimicag.2020.106191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106191</ArticleId><ArticleId IdType="pmc">PMC7546273</ArticleId><ArticleId IdType="pubmed">33045354</ArticleId></ArticleIdList></Reference><Reference><Citation>Enseleit F., Sudano I., P&#xe9;riat D., Winnik S., Wolfrum M., Flammer A.J., Fr&#xf6;hlich G.M., Kaiser P., Hirt A., Haile S.R., et al. Effects of Pycnogenol on Endothelial Function in Patients with Stable Coronary Artery Disease: A Double-Blind, Randomized, Placebo-Controlled, Cross-over Study. Eur. Heart J. 2012;33:1589&#x2013;1597. doi: 10.1093/eurheartj/ehr482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr482</ArticleId><ArticleId IdType="pubmed">22240497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihaila R.G. A Minireview on NHE1 Inhibitors. A Rediscovered Hope in Oncohematology. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2015;159:519&#x2013;526. doi: 10.5507/bp.2015.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.5507/bp.2015.060</ArticleId><ArticleId IdType="pubmed">26725705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazmuri R.J., Radhakrishnan J., Ayoub I.M. Sodium-Hydrogen Exchanger Isoform-1 Inhibition: A Promising Pharmacological Intervention for Resuscitation from Cardiac Arrest. Molecules. 2019;24:1765. doi: 10.3390/molecules24091765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24091765</ArticleId><ArticleId IdType="pmc">PMC6538998</ArticleId><ArticleId IdType="pubmed">31067690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeves A.M., Ennis I.L. Na+/H+ Exchanger and Cardiac Hypertrophy. Hipertens. Y Riesgo Vasc. 2020;37:22&#x2013;32. doi: 10.1016/j.hipert.2019.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hipert.2019.09.002</ArticleId><ArticleId IdType="pubmed">31601481</ArticleId></ArticleIdList></Reference><Reference><Citation>Previtali S.C., Gidaro T., D&#xed;az-Manera J., Zambon A., Carnesecchi S., Roux-Lombard P., Spitali P., Signorelli M., Szigyarto C.A.-K., Johansson C., et al. Rimeporide as a FIrst- in-Class NHE-1 Inhibitor: Results of a Phase Ib Trial in Young Patients with Duchenne Muscular Dystrophy. Pharmacol. Res. 2020;159:104999. doi: 10.1016/j.phrs.2020.104999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104999</ArticleId><ArticleId IdType="pmc">PMC7482441</ArticleId><ArticleId IdType="pubmed">32535224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>